These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34078814)

  • 1. Incorrect Holding Angle of Dry Powder Inhaler during the Drug-Loading Step Significantly Decreases Output Efficiency.
    Suenaga K; Hira D; Ishido E; Koide H; Ueshima S; Okuda T; Yamaguchi M; Morita SY; Okamoto H; Okano T; Nakano Y; Terada T; Kakumoto M
    Biol Pharm Bull; 2021; 44(6):822-829. PubMed ID: 34078814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
    Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
    Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide + formoterol delivered via Spiromax
    Lewis A; Torvinen S; Dekhuijzen PNR; Chrystyn H; Melani A; Zöllner Y; Kolbe K; Watson AT; Blackney M; Plich A
    Respir Med; 2017 Aug; 129():179-188. PubMed ID: 28732829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Time Particle Emission Monitoring for the Non-Invasive Prediction of Lung Deposition via a Dry Powder Inhaler.
    Hatazoe S; Hira D; Kondo T; Ueshima S; Okano T; Hamada S; Sato S; Terada T; Kakumoto M
    AAPS PharmSciTech; 2024 May; 25(5):109. PubMed ID: 38730125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
    Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
    NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.
    Scott LJ
    Drugs; 2012 Feb; 72(3):395-414. PubMed ID: 22316354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
    Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
    BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
    Cazzola M; Ora J; Di Paolo A; Puxeddu E; Calzetta L; Rogliani P
    Pulm Pharmacol Ther; 2016 Aug; 39():48-53. PubMed ID: 27344046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort
    Gillen M; Forte P; Svensson JO; Lamarca R; Burke J; Rask K; Larsdotter Nilsson U; Eckerwall G
    Pulm Pharmacol Ther; 2018 Oct; 52():7-17. PubMed ID: 30077809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Errors in Aerosol Inhaler Use and Their Effects on Maternal and Fetal Outcomes among Pregnant Asthmatic Women (Subanalysis from QAKCOP Study).
    Ibrahim WH; Rasul F; Ahmad M; Bajwa AS; Alamlih LI; El Arabi AM; Al-Mohannadi D; Siddiqui MY; Al-Sheikh IS; Ibrahim AA
    Can Respir J; 2018; 2018():7649629. PubMed ID: 30662579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort
    Bagherisadeghi G; Larhrib EH; Chrystyn H
    Int J Pharm; 2017 Apr; 522(1-2):137-146. PubMed ID: 28254655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
    Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
    Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma.
    Lähelmä S; Vahteristo M; Metev H; Taseva M; Stamatova N; Bartha A; Schlezák J; Sairanen U
    Respir Med; 2016 Nov; 120():31-35. PubMed ID: 27817813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life association between inhaler technique, patient preference and asthma control in patients with uncontrolled asthma switched to budesonide/formoterol DuoResp® Spiromax® combination.
    Roche N; Aguilaniu B; Paternotte S; Dallery N
    J Asthma; 2022 Apr; 59(4):765-774. PubMed ID: 33493074
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of inhaler technique and patient satisfaction with fixed-combination budesonide/formoterol dry-powder inhaler in chronic obstructive pulmonary disease (COPD): data on real-life clinical practice in Turkey.
    Öztürk C; Kaya A; Bilgin C; Yücesoy L; İkidağ B; Demirel M; Başlılar Ş; Şaylan B; Senol T; Ağanoğlu S; Can G; Doğrul MI; Çam M; Erdoğan N; Batum Ö; Turan MO; Demir C; Torun Ş; Cirit M; Turan M; Keleşoğlu A; Yaşar S; Uzunay Ö; Melek K; Altıparmak O
    Tuberk Toraks; 2012; 60(4):301-13. PubMed ID: 23289459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
    Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches.
    Soulele K; Macheras P; Karalis V
    Pulm Pharmacol Ther; 2018 Feb; 48():168-178. PubMed ID: 29223508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.
    van der Palen J; Thomas M; Chrystyn H; Sharma RK; van der Valk PD; Goosens M; Wilkinson T; Stonham C; Chauhan AJ; Imber V; Zhu CQ; Svedsater H; Barnes NC
    NPJ Prim Care Respir Med; 2016 Nov; 26():16079. PubMed ID: 27883002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.